Relative risk of haematopoietic malignancies including 95% confidence intervals (CI) in three Swedish cohorts of patients with RA
| Type | Inpatient Register RA | Early Arthritis cohort | TNF antagonist cohort | |||
|---|---|---|---|---|---|---|
| No | SIR (95% CI) | No | SIR (95% CI) | No | SIR (95% CI) | |
| Follow up from 1990 (or entry into cohort, if later) until 31 December 2003. Relative risk estimated comparing each cohort with the general Swedish population, adjusting for age, sex, and calendar period. | ||||||
| CLL, chronic lymphocytic leukaemia. | ||||||
| All haematopoietic malignancies | 481 | 1.7 (1.5 to 1.8) | 15 | 1.6 (0.9 to 2.6) | 11 | 2.1 (1.1 to 3.8) |
| Malignant lymphoma including CLL | 319 | 1.9 (1.7 to 2.1) | 11 | 2.0 (1.0 to 3.5) | 9 | 2.9 (1.3 to 5.5) |
| Plasma cell neoplasms | 45 | 0.8 (0.6 to 1.1) | 0 | 0.0 (0.0 to 2.2) | 0 | 0.0 (0.0 to 4.2) |
| Leukaemia excluding CLL | 107 | 2.1 (1.7 to 2.5) | 4 | 2.2 (0.6 to 5.7) | 2 | 2.0 (0.2 to 7.3) |
| Acute lymphatic leukaemia | 2 | 0.9 (0.1 to 3.2) | 0 | 0.0 (0.0 to 40.8) | 0 | 0.0 (0.0 to 61.1) |
| Acute myeloid leukaemia | 68 | 2.4 (1.9 to 3.0) | 4 | 4.3 (1.2 to 10.9) | 0 | 0.0 (0.0 to 7.4) |
| Chronic myeloid leukaemia | 13 | 2.4 (1.3 to 4.1) | 0 | 0.0 (0.0 to 17.7) | 0 | 0.0 (0.0 to 27.0) |
| Other or undefined leukaemia | 23 | 1.5 (1.0 to 2.3) | 0 | 0.0 (0.0 to 6.8) | 2 | 6.8 (0.8 to 24.7) |
| Polycytaemia vera | 10 | 0.9 (0.4 to 1.6) | 0 | 0.0 (0.0 to 10.1) | 0 | 0.0 (0.0 to 18.5) |